Literature DB >> 16716568

Are deficits in executive sub-processes simply reflecting more general cognitive decline in schizophrenia?

Gary Donohoe1, Sarah Clarke, Derek Morris, Jeanne-Marie Nangle, Siobhan Schwaiger, Michael Gill, Aiden Corvin, Ian H Robertson.   

Abstract

BACKGROUND: Schizophrenia is associated with both global and specific cognitive deficits. We sought to investigate whether deficits in executive subcomponents differed in their relationship to global cognitive impairments.
METHOD: 95 patients were classified according to pre-morbid and current general cognitive ability as having either (a) intact pre-morbid and current general cognitive ability; (b) intact pre-morbid but deteriorated current ability, and (c) deteriorated both pre-morbid and current cognitive ability. All patients completed measures of verbal and spatial working memory, sustained selective attention, attentional set sifting, and inhibitory control.
RESULTS: Deficits on both measures of working memory were associated with general cognitive ability. None of the attentional control deficits observed were associated with general ability. Further, spatial working memory deficits were also associated with more severe negative symptoms.
CONCLUSIONS: These results provide further evidence of the discreet nature of attentional deficits in schizophrenia. By contrast, this study suggests that working memory deficits may to some extent index more general cognitive decline. Awareness of such overlap is important for schizophrenia genetics studies where working memory measures has been used to index supposedly discreet aspects of cognitive dysfunction.

Entities:  

Mesh:

Year:  2006        PMID: 16716568     DOI: 10.1016/j.schres.2006.03.041

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  7 in total

1.  Clinical value of the sTim‑3 level in chronic kidney disease.

Authors:  Lingli Chen; Yuan Qin; Bo Lin; Xiaomei Yu; Shaoxiong Zheng; Xiumei Zhou; Xiaobin Liu; Yigang Wang; Biao Huang; Juan Jin; Liang Wang
Journal:  Exp Ther Med       Date:  2022-07-29       Impact factor: 2.751

2.  The Impact of Childhood Adversity on Cognitive Development in Schizophrenia.

Authors:  Ruth Wells; Isabella Jacomb; Vaidy Swaminathan; Suresh Sundram; Danielle Weinberg; Jason Bruggemann; Vanessa Cropley; Rhoshel K Lenroot; Avril M Pereira; Andrew Zalesky; Chad Bousman; Christos Pantelis; Cynthia Shannon Weickert; Thomas W Weickert
Journal:  Schizophr Bull       Date:  2020-01-04       Impact factor: 9.306

3.  Executive attention impairment in first-episode schizophrenia.

Authors:  Gricel Orellana; Andrea Slachevsky; Marcela Peña
Journal:  BMC Psychiatry       Date:  2012-09-22       Impact factor: 3.630

4.  Evidence towards a continuum of impairment across neurodevelopmental disorders from basic ocular-motor tasks.

Authors:  Daniela Canu; Chara Ioannou; Katarina Müller; Berthold Martin; Christian Fleischhaker; Monica Biscaldi; André Beauducel; Nikolaos Smyrnis; Ludger Tebartz van Elst; Christoph Klein
Journal:  Sci Rep       Date:  2022-10-03       Impact factor: 4.996

5.  Mental state decoding v. mental state reasoning as a mediator between cognitive and social function in psychosis.

Authors:  Nicola McGlade; Caragh Behan; Judy Hayden; Therese O'Donoghue; Rosie Peel; Farhan Haq; Michael Gill; Aiden Corvin; Eadbhard O'Callaghan; Gary Donohoe
Journal:  Br J Psychiatry       Date:  2008-07       Impact factor: 9.319

6.  The impact of premorbid and current intellect in schizophrenia: cognitive, symptom, and functional outcomes.

Authors:  Ruth Wells; Vaidy Swaminathan; Suresh Sundram; Danielle Weinberg; Jason Bruggemann; Isabella Jacomb; Vanessa Cropley; Rhoshel Lenroot; Avril M Pereira; Andrew Zalesky; Chad Bousman; Christos Pantelis; Cynthia Shannon Weickert; Thomas W Weickert
Journal:  NPJ Schizophr       Date:  2015-11-04

7.  Potential Role of Oestrogen Modulation in the Treatment of Neurocognitive Deficits in Schizophrenia.

Authors:  Thomas W Weickert; Katherine M Allen; Cynthia S Weickert
Journal:  CNS Drugs       Date:  2016-02       Impact factor: 5.749

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.